In 2006, after the completion of the major review of pharmaceutical legislation, the Commission published ideas to further improve the legislation of proprietary medicinal product variation applications. The basic idea was: Simplification of…

Re-emergence of a case in Bucharest.

Occurrence of a confirmed case in the province of Bologna/Ferrara.

The following quality defect has been identified in the drug product Ionsys (Fentanyl) 40 microgram per dose iontophoretic transdermal system: A defect in the IONSYS systems may potentially cause the system to self-activate. See related files.

Exchange of unbuffered and weakly buffered infusion solutions. See associated files.

Information to ensure the safety of Neupro. See related files.

Communication from the Federal Office for Safety in Health Care on Gardasil. You related file.

Information on the suspension of marketing of parenterally administrable drug products containing aprotinin. See related files.

Information on market withdrawal of Clobutinol-containing drugs (Silomat®) up to and including patient level. See related files.

Information on processing open registration and amendment requests submitted prior to Jan. 1, 2006. See related file.